Neurones AI Stock Analysis
Want to see FR:NRO full AI Analyst Report?
Neurones (NRO) AI Stock Analysis
Neurones
(Paris:NRO)
The overall score of 75 reflects a company with strong financial fundamentals, particularly its pristine balance sheet and healthy cash flows. The stock's technical trend is positive but warrants caution due to overbought signals. Valuation is fair and supported by an attractive dividend yield. The primary risk is the observed deceleration in revenue growth and slight margin pressure.
Neurones (NRO) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 1.00B
- Dividend Yield
- 3.39%
- Average Volume (3M)
- 6,349
- Price to Earnings (P/E)
- 18.1
- Beta (1Y)
- 0.41
- Revenue Growth
- 6.68%
- EPS Growth
- 9.16%
- Country
- France
- Employees
- 7,329
- Sector
- General
- Sector Strength
- 55
- Industry
- Information Technology Services
Neurones Business Overview & Revenue Model
Company Description
Neurones S.A., an information technology (IT) services provider founded in 1984 and headquartered in Nanterre, France, operates with a global reach. The company delivers a broad spectrum of services encompassing infrastructure, application developmen...
How the Company Makes Money
Neurones makes money primarily by selling professional services to business and public-sector clients under consulting and IT services engagements. Revenue is mainly generated from (1) time-and-materials consulting and engineering assignments billed...
Neurones Financial Statement Overview
Summary
Neurones demonstrates solid financial health with a robust balance sheet (Score: 88), strong cash flow generation (Score: 80), and consistent profitability (Income Score: 72). Low leverage and high free cash flow conversion are key strengths, though slowing revenue growth and slight EBIT margin compression are noted.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
80Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 887.74M | 857.20M | 810.40M | 741.17M | 665.38M | 579.88M |
| Gross Profit | 504.95M | 90.04M | 388.76M | 346.76M | 81.64M | 69.73M |
| EBITDA | 96.35M | 90.32M | 95.56M | 96.63M | 88.72M | 76.33M |
| Net Income | 55.29M | 52.07M | 52.50M | 49.41M | 44.24M | 37.71M |
Balance Sheet | ||||||
| Total Assets | 730.02M | 749.03M | 725.69M | 674.25M | 616.22M | 567.82M |
| Cash, Cash Equivalents and Short-Term Investments | 301.88M | 340.78M | 326.49M | 297.76M | 272.06M | 265.17M |
| Total Debt | 41.30M | 36.96M | 42.02M | 43.98M | 35.57M | 35.32M |
| Total Liabilities | 296.68M | 284.16M | 289.52M | 266.34M | 240.63M | 214.90M |
| Stockholders Equity | 376.16M | 399.98M | 378.10M | 354.39M | 330.58M | 311.56M |
Cash Flow | ||||||
| Free Cash Flow | 88.59M | 70.33M | 72.34M | 54.09M | 44.33M | 58.10M |
| Operating Cash Flow | 100.76M | 80.77M | 84.38M | 72.08M | 54.94M | 64.68M |
| Investing Cash Flow | -23.85M | -21.16M | -19.69M | -21.57M | -12.26M | -10.62M |
| Financing Cash Flow | -67.63M | -45.11M | -34.48M | -27.06M | -36.08M | -55.42M |
Neurones Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NRO, the sentiment is Positive. The current price of 41.25 is above the 20-day moving average (MA) of 38.53, above the 50-day MA of 37.13, and above the 200-day MA of 36.02, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 73.23 is Negative, neither overbought nor oversold. The STOCH value of 90.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NRO.
Neurones Peers Comparison
Overall Rating
FR:WAVE83Outperform
FR:SOP77Outperform
FR:NRO75Outperform
FR:CAP70Outperform
FR:ATE66Neutral
FR:ATO42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | EUR 875.34M | 10.60 | 12.19% | 1.41% | 1.13% | 8.32% | |
| 77Outperform | EUR 3.80B | 12.68 | 14.45% | 2.69% | 1.62% | 12.95% | |
| 75Outperform | EUR 978.73M | 18.09 | 14.25% | 3.39% | 6.68% | 9.16% | |
| 70Outperform | EUR 21.45B | 15.63 | 11.82% | 2.67% | 6.23% | -11.48% | |
| 66Neutral | EUR 3.07B | 21.58 | 6.19% | 1.72% | 0.11% | -6.28% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 42Neutral | EUR 478.90M | -0.39 | 117.34% | ― | -14.39% | -173.10% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:NRO | Neurones | 41.25 | 0.54 | 1.33% | |
| FR:ATE | ALTEN | 87.40 | 21.66 | 32.94% | |
| FR:ATO | Atos SE | 23.74 | -19.43 | -45.00% | |
| FR:CAP | Capgemini | 127.40 | -0.19 | -0.15% | |
| FR:SOP | Sopra Steria | 197.30 | 71.44 | 56.76% | |
| FR:WAVE | Wavestone SA | 35.40 | -12.52 | -26.13% |
Neurones Corporate Events
NEURONES Reports 7.1% Organic Growth in Third Quarter
NEURONES is a French management consulting and digital services company that helps major organizations deliver digital projects, transform IT infrastructures and accelerate AI adoption. Its activities include data and AI, digital projects, IT service...
Neurones Releases Half-Year Financial Report for First Half of 2026
Neurones has published its half-year financial report for the period ending 30 June 2026, providing stakeholders with an overview of its activity, consolidated financial statements and related certifications.The release highlights that the report inc...
Neurones Delivers Strong First-Half 2026 Growth and Reaffirms Margin Guidance
Neurones reported first-half 2026 revenues of €454.8 million, up 7.2% year-on-year, driven largely by 6.9% organic growth and confirming its momentum in digital consulting and IT services. Operating profit rose 19.9% to represent 8.7% of revenue, whi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
